DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacologic Relapse Prevention for Alcoholic Smokers

Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alcoholism; Smoking

Intervention: bupropion (Wellbutrin) (Drug); Placebo (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Mayo Clinic

Official(s) and/or principal investigator(s):
Richard D Hurt, MD, Principal Investigator, Affiliation: Mayo Clinic

Summary

This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.

Clinical Details

Official title: Pharmacologic Relapse Prevention for Alcoholic Smokers

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Will bupropion reduce relapse to smoking compared to placebo

Secondary outcome: Does matching the dose of nicotine patches to nicotine levels help increase smoking abstinence

Detailed description: The purpose of this trial was to recruit 292 recovering alcoholic smokers (abstinent from alcohol for a minimum of 1 year), who want to stop smoking and provide them with 100% nicotine replacement. The 100% nicotine replacement will be undertaken using a nicotine patch. By measuring their nicotine levels at study entry we can determine the patch dosing needed. The patch dosing will vary from 22 mg to 44 mg. Those who are able to achieve tobacco abstinence by week 8 will enter a relapse prevention phase for the remaining 44 weeks. In this phase, they will be randomized to active or placebo bupropion (300 mg/day). After 44 weeks of the relapse prevention trial (at week 52 of study participation), they will enter a post medication follow up for 6 months.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- History of alcohol dependence and at least one year of abstinence from alcohol

intake.

- Has a history of smoking 20 or more cigarettes per day for the prior year.

- Can read and write English.

- Stated ability to fully participate in the study and keep all scheduled appointments.

- Has provided written informed consent.

- General good health.

Exclusion Criteria:

- Recent history (within three months) of a clinically significant myocardial

infarction, unstable angina pectoris, serious cardiac arrhythmia or any other medical condition which the physician investigator deems incompatible with study participation.

- Current major depression. A past history of major depression will not be an

exclusionary criteria.

- Current or previous use of bupropion (Wellbutrin).

- Active non- nicotine drug dependence.

- Past or current history of bipolar disorder, pain disorder or psychosis,

schizophrenia, or other major psychiatric disorders.

- Current medically indicated use of psychiatric drugs.

- Females who are pregnant, lactating, or likely to become pregnant during the first

year which includes the nicotine patch and bupropion (Wellbutrin) phase.

- History of severe skin allergies or evidence of severe chronic skin disorders.

- Current use of nicotine containing medication or tobacco products other than

cigarettes.

- Current use (within 30 days of initiation of patch therapy) of the following

medications for smoking cessation: clonidine, buspirone, or doxepin.

- A predisposition to seizures.

- A history of or current diagnosis of anorexia nervosa or bulimia.

- Medical disorder that would interfere with the absorption, metabolism, or excretion

of bupropion (Wellbutrin).

Locations and Contacts

Mayo Clinic Rochester, Rochester, Minnesota 55905, United States
Additional Information

Starting date: June 1998
Last updated: October 18, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017